GLP-1s for Perimenopause Weight Loss: Menopause-Specific Research and Timelines

Yes, GLP-1s can help you lose weight during perimenopause. In menopause-specific analyses, peri and postmenopausal women lost about as much weight as younger women, including less fat around the waist. The research in this group is still small, so most timeline expectations come from general trials where slow starts were common.

What do menopause-specific studies show?

A scoping review found GLP-1s were linked with more weight loss and less central adiposity, which means less belly fat stored around the waist, in menopausal and postmenopausal women. A few studies in that review also noted fewer vasomotor symptoms, which means hot flashes and night sweats, and better cardiovascular markers such as cholesterol. The authors said the research is limited and larger trials in menopausal women are needed scoping review.

A 2025 review in Current Opinion in Obstetrics and Gynecology called GLP-1s consistently the most effective medicines for weight loss and a valuable tool for peri and postmenopausal women, while also noting very little data specific to this group review.

The most detailed hormone therapy comparison followed 106 postmenopausal women on semaglutide. The 16 women also using hormone therapy, which means estrogen with or without progesterone for menopause symptoms, lost more weight at every check. At 12 months they had lost 16% of body weight compared with 12% without hormone therapy. Both groups improved blood sugar, blood pressure and lipids Mayo cohort. That was a small, look-back study, so it shows a link, not a promise that hormone therapy raises loss for everyone.

A separate analysis of 2,542 women from the SURMOUNT-1, SURMOUNT-3 and SURMOUNT-4 tirzepatide trials followed women up to 88 weeks. Perimenopausal and postmenopausal women lost weight comparably to premenopausal women when they used tirzepatide with lifestyle changes menopause analysis.

How long before you see meaningful loss?

Menopause studies tell you whether loss happens. General trials tell you how long it can take. In a post hoc analysis of 1,545 people on tirzepatide in SURMOUNT-1, 278 people or 18% had lost less than 5% at week 12. By week 24, 70% of those slower starters had reached 5% or more loss. By week 72, 90% had reached 5% or more. The average time to reach 5% for that slower group was about 25 weeks late-responder analysis.

That pattern matters in perimenopause because early weeks can feel discouraging. A smaller number on the scale at 12 weeks did not mean later months failed for most people in that analysis. If you want help weighing a slow start, side effects and other options, you can start your HOD plan through the quiz for clinician review.

What women report

These quotes come from individual women in r/AskWomen, publication date not listed, and describe personal experience thread:

• "all I could eat was toast, basically" — r/AskWomen, publication date not listed
• "I hit my goal weight of 150 in September 2025 without tracking a single calorie" — r/AskWomen, publication date not listed
• "With GLP-1 (tirzepatide), I lost my appetite pretty quickly." — r/AskWomen, publication date not listed
• "I get nausea now and then but I just take some ginger lozenges." — r/AskWomen, publication date not listed
• "It's not inexpensive but it's been effective for me." — r/AskWomen, publication date not listed

The pattern across those reports was appetite dropping within weeks, rough early days with nausea and very small meals, then a slower build. One woman described starting at 205 lb in June 2024 and reaching 150 lb by September 2025. Another described appetite change within 2.5 weeks alongside cost concern. These stories describe individuals. They do not show how well or safely the drug works for others.